This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vandamme, B. Articles by De Grève, J. Search for Related Content PubMed PubMed Citation Articles by Vandamme, B. Articles by De Grève, J.

Deletion of Chromosome 11p13–11p15.5 Sequences in Invasive Human Ovarian Cancer Is a Subclonal Progression Factor¹

Laboratorium Medische Genetika [B. V., W. L., K. A., J. D. G.]; Oncologisch Centrum [P. D. S., J. D. G.]; Laboratorium Experimentele Pathologie [C. B.]; and Laboratoire de Cytogénétique [E. V.], Akademisch Ziekenhuis, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Jette, Belgium

³ To whom requests for reprints should be addressed, at Laboratorium Medische Genetika, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Jette, Belgium.

In human ovarian cancer, multiple specific chromosomal deletions can be found by cytogenetic analysis or molecular techniques such as restriction fragment length polymorphism probing. This work confirms the loss HRAS alleles in 1 out of 2 cases of invasive ovarian cancer as determined in 32 samples or cell lines derived from 19 patients. Results with other polymorphic probes indicate that a consensus deletion probably includes 11p15.5–11p13. Tumor suppressor genes might be located in the deleted area, and deletion of the gene might then play a role in disease progression. Examination of DNA from distinct tumor sites of individual patients indicates clonal heterogeneity in the malignant cell population, indicating that loss of 11p sequences is a late event in the disease progression. Loss of alternate 11p alleles at different disease sites in one patient is inconsistent with the current model of tumor suppressor gene inactivation. The 11p deletion seems to be limited to ovarian cancers in younger patients. Eight novel permanent ovarian cancer cell lines, previously not described in the literature and derived from tumor sites from five patients, were included in the current analysis.

¹ Supported by the Belgische Sportvereniging tegen Kanker, Het Belgisch Werk tegen Kanker, Vlaamse Advies Commissie voor Kankerpreventie, and Grant 3.0088.90 from the Fonds voor Geneeskundig en Wetenschappelijk Onderzoek.

² K. A. is a postgraduate student in medical research at the Vrije Universiteit Brussel.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/10/91. Accepted 9/17/92.

This article has been cited by other articles:

				X. L. Xu, L. C. Wu, F. Du, A. Davis, M. Peyton, Y. Tomizawa, A. Maitra, G. Tomlinson, A. F. Gazdar, B. E. Weissman, et al. Inactivation of Human SRBC, Located within the 11p15.5-p15.4 Tumor Suppressor Region, in Breast and Lung Cancers Cancer Res., November 1, 2001; 61(21): 7943 - 7949. [Abstract] [Full Text] [PDF]

				B. Gawin, A. Niederführ, N. Schumacher, H. Hummerich, P. F.R. Little, and M. Gessler A 7.5 Mb Sequence-Ready PAC Contig and Gene Expression Map of Human Chromosome 11p13-p14.1 Genome Res., November 1, 1999; 9(11): 1074 - 1086. [Abstract] [Full Text]

				M. E. Carney, G. L. Maxwell, J. M. Lancaster, C. Gumbs, J. Marks, A. Berchuck, and P. A. Futreal Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers Reproductive Sciences, September 1, 1998; 5(5): 281 - 285. [Abstract] [PDF]